Mohamed Amine Chaabouni / Rania Kharrat
Librería Samer Atenea
Kálamo Books
Librería Elías (Asturias)
Librería Kolima (Madrid)
Librería Proteo (Málaga)
The incidence of differentiated thyroid microcarcinoma (mCD) has increased significantly due to incidental diagnosis. Although classified as a carcinoma, its natural history is most often indolent, posing a challenge regarding the aggressiveness of its management.Objective: To evaluate the clinico-pathological characteristics and disease progression profile of mCD, and to harmonize treatment and follow-up protocols in light of the most recent scientific data.Results: The prognosis for mCD is excellent, with a near-zero disease-specific mortality rate (< 0.5%) and a locoregional recurrence rate of less than 8% for low-risk forms. Its management has changed radically. The 2025 ATA recommendations endorse therapeutic de-escalation. Post-treatment follow-up is now streamlined and personalized through dynamic stratification.Conclusion: Recent international guidelines definitively endorse a minimalist and individualized approach to care in order to preserve patients’ quality of life while ensuring their oncological safety.